サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1798843

認知症治療薬の世界市場

Dementia Drugs

出版日
ページ情報
英文 286 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
認知症治療薬の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

認知症治療薬の世界市場は2030年までに212億米ドルに達する見込み

2024年に160億米ドルと推定される認知症治療薬の世界市場は、2024年から2030年にかけてCAGR 4.9%で成長し、2030年には212億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるレビー小体型認知症は、CAGR 3.8%を記録し、分析期間終了時には77億米ドルに達すると予測されます。パーキンソン病認知症セグメントの成長率は、分析期間中CAGR 6.1%と推定されます。

米国市場は43億米ドルと推定、中国はCAGR 7.6％で成長予測

米国の認知症治療薬市場は、2024年に43億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに41億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と4.8%と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

世界の認知症治療薬市場- 主要動向と促進要因まとめ

認知症治療薬の需要が世界の健康上の重要課題になりつつあるのはなぜか？

主に記憶、認知、行動に影響を及ぼす進行性の神経変性疾患である認知症は、最も差し迫った世界の公衆衛生上の課題として認識されつつあります。特に先進経済諸国や新興経済諸国では、人口の高齢化に伴い、認知症の罹患率が急速に上昇しており、その大部分をアルツハイマー病が占めています。認知症の社会的・経済的負担は計り知れず、患者だけでなく家族、介護者、ヘルスケアシステムにも影響を及ぼしています。このような有病率の高まりにより、疾患の進行を遅らせ、症状を管理し、生活の質を改善する効果的な薬理学的治療に対する緊急の需要が高まっています。現在、利用可能な認知症治療薬は、根本的な病態よりも神経伝達物質の不均衡や行動の合併症に対処する対症療法が中心です。しかし、アミロイド斑、タウのもつれ、神経炎症経路を標的とした疾患修飾療法の研究開発は、その緊急性の高まりから集中的に行われています。根治的な治療法がないことや、他の加齢関連疾患と併存することが多いというこの疾患の複雑な性質により、より良い管理方法の必要性が高まっています。早期診断の取り組みや認知度向上キャンペーンにより、より多くの人々が早期に治療を受けるようになり、薬物療法の対象となる患者層が拡大しています。ヘルスケアプロバイダーや政策立案者は認知症管理をますます優先するようになっており、その結果、臨床試験への資金提供や包括的なヘルスケアプランが増加しています。このような人口統計学的、社会的、医学的要因の収束により、認知症治療薬市場は、より広範な神経治療薬分野において長期的な戦略的重要性を持つ焦点となっています。

科学技術の進歩は認知症治療薬開発の将来をどのように形成しているか？

神経科学、分子生物学、バイオテクノロジーの進歩は認知症治療薬開発の軌道を変えつつあり、認知機能低下の根本原因に取り組む新たな希望をもたらしています。近年、調査は従来のコリンエステラーゼ阻害薬やNMDA受容体拮抗薬にとどまらず、アミロイドβ凝集、タウタンパク質のリン酸化、シナプス可塑性、神経炎症など、新たなターゲットの探索へと拡大しています。ゲノミクスとプロテオミクスの飛躍的な開発により、さまざまな認知症に関連するバイオマーカーや遺伝的危険因子が同定され、より個別化された的確な薬剤開発が可能になりつつあります。PETスキャンやMRIを用いた容積分析などの高度な画像診断技術の導入により、より早期の診断や、より正確な疾患進行の追跡が可能になり、これは新しい治療法の有効性を評価する上で極めて重要です。臨床試験のデザインも進化しており、適応試験モデル、実世界のデータ統合、デジタル認知評価ツールなどが、研究者がより有意義でタイムリーな知見を収集するのに役立っています。並行して、製薬会社は人工知能と機械学習を活用して、化合物探索の加速化、治療結果の予測、試験募集の最適化を図っています。アミロイド蛋白やタウ蛋白を標的とする生物製剤やモノクローナル抗体は規制当局のパイプラインを通過しつつあり、疾患修飾戦略へのシフトを示唆しています。賛否両論があるにもかかわらず、一部の市場ではアミロイドを標的とする薬剤の承認が早まったことで、この分野への関心と投資が新たに高まっています。さらに、複数の病態プロセスに同時に対処する併用療法は、認知症治療のより包括的なアプローチとして支持を集めています。こうした科学技術の革新は、治療の可能性を広げるだけでなく、認知症治療薬市場における有効性と安全性の基準を再定義しています。

認知症治療薬市場の拡大と投資を促進する動向とは？

世界の認知症治療薬市場の拡大には、人口動態、ヘルスケアの優先順位、投資戦略の変化を反映した複数の動向が交錯しています。最も影響力のある動向のひとつは高齢化であり、特に北米、欧州、日本、そして平均寿命が延びつつあるアジアやラテンアメリカの一部で顕著になっています。認知症の最大の危険因子は加齢であるため、こうした人口動態の変化は、患者数の増加と治療ソリューションの持続的な市場拡大につながっています。同時に、アルツハイマー病協会や世界保健機関（WHO）などの団体が主導する啓発キャンペーンや教育活動は、偏見をなくし、早期受診を促し、診断率を高めています。ヘルスケアシステムは、高齢者の定期検診に認知機能スクリーニングを組み込んだり、認知症関連治療の保険適用を拡大したりすることで適応しています。また、ベンチャーキャピタルや大手製薬会社が神経学や神経変性疾患研究に再び関心を示すなど、投資家心理の変化も顕著です。バイオテクノロジー新興企業と既存の医薬品メーカーとの戦略的パートナーシップは一般的になりつつあり、より迅速な技術革新と幅広い臨床開発を可能にしています。さらに、数カ国の規制当局が認知症治療、特にアンメットメディカルニーズに対応する治療薬の承認に柔軟性を見せており、有望な候補薬の市場参入が加速しています。市場の多様化もトレンドの一つであり、医薬品開発企業はアルツハイマー病以外にも血管性認知症、前頭側頭型認知症、レビー小体型認知症など様々なタイプの認知症に対する動向を探っています。このような治療領域の拡大により、市場はより広範な臨床症状や患者のニーズに対応し、ダイナミックであり続けています。

世界の認知症治療薬市場の成長を促進する主な要因は？

認知症治療薬市場の成長は、医療、人口統計、技術、経済の各要因の融合によって牽引されています。特に新興経済諸国では、高齢化と長寿化によって認知症患者が世界的に急増しています。この人口動態の変化により、長期的な医療を必要とする患者層が継続的に拡大しており、効果的な薬理学的治療に対する需要が高まっています。もう一つの重要な推進力は、早期診断への注目の高まりであり、これは画像診断、バイオマーカー同定、認知評価ツールの改善によって促進されています。早期介入は治療効果の可能性を高め、予防や疾患修飾戦略の扉を開きます。製薬会社やバイオテクノロジー企業は、政府からの助成金や慈善事業による資金援助を受けて研究開発に積極的に投資し、このチャンスに応えています。規制の枠組みが進化し、大きなアンメットニーズに対応する医薬品の迅速な承認経路がサポートされるようになったことも、イノベーションをさらに後押ししています。世界の医療費の増加、特に神経学と老人医療における増加は、既存治療と新興治療の両方への幅広いアクセスを可能にしています。患者アドボカシーや介護者支援ネットワークも、より良い治療選択肢に対する需要を喚起し、公共政策に影響を与える役割を担っています。臨床試験やドラッグデリバリーの技術統合により、治療結果のモニタリングや治療の個別化が容易になりつつあります。これらの促進要因は、認知症がもたらす社会経済的負担に対する認識の高まりと相まって、認知症治療薬市場が成長し続け、革新し続け、神経変性疾患管理の複雑な課題に適応し続けることを確実なものにしています。

セグメント

適応症（レビー小体型認知症、パーキンソン病性認知症、アルツハイマー病、血管性認知症、その他の適応症）、薬剤クラス（MAO阻害薬クラス、グルタミン酸阻害薬クラス、コリンエステラーゼ阻害薬クラス）

調査対象企業の例

  • AbbVie Inc.
  • Acadia Pharmaceuticals
  • Amneal Pharmaceuticals
  • Biogen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GSK plc
  • Grifols, S.A.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38695

Global Dementia Drugs Market to Reach US$21.2 Billion by 2030

The global market for Dementia Drugs estimated at US$16.0 Billion in the year 2024, is expected to reach US$21.2 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Lewy Body Dementia, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$7.7 Billion by the end of the analysis period. Growth in the Parkinson's Disease Dementia segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 7.6% CAGR

The Dementia Drugs market in the U.S. is estimated at US$4.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.1 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Dementia Drugs Market - Key Trends & Drivers Summarized

Why Is the Demand for Dementia Drugs Becoming a Critical Global Health Priority?

Dementia, a progressive neurodegenerative disorder primarily affecting memory, cognition, and behavior, is increasingly being recognized as one of the most pressing global public health challenges. As populations age, particularly in developed and emerging economies, the incidence of dementia is rising rapidly, with Alzheimer’s disease accounting for the majority of cases. The social and economic burden of dementia is immense, affecting not only patients but also families, caregivers, and healthcare systems. This escalating prevalence is driving urgent demand for effective pharmacological treatments that can slow disease progression, manage symptoms, and improve quality of life. Currently, available dementia drugs are largely symptomatic, addressing neurotransmitter imbalances or behavioral complications rather than the underlying disease pathology. However, the growing urgency has spurred intensive research and development in disease-modifying therapies aimed at targeting amyloid plaques, tau tangles, and neuroinflammatory pathways. The need for better management options is heightened by the lack of curative treatments and the complex nature of the disease, which often coexists with other age-related conditions. Early diagnosis initiatives and growing awareness campaigns are prompting more individuals to seek treatment sooner, expanding the potential patient population for drug therapies. Healthcare providers and policymakers are increasingly prioritizing dementia management, which is resulting in more funding for clinical trials and more inclusive healthcare plans. This convergence of demographic, social, and medical factors is making the dementia drugs market a focal point of long-term strategic importance within the broader neurological therapeutics space.

How Are Scientific and Technological Advances Shaping the Future of Dementia Drug Development?

Advances in neuroscience, molecular biology, and biotechnology are reshaping the trajectory of dementia drug development, offering new hope for tackling the root causes of cognitive decline. In recent years, research has expanded beyond the traditional focus on cholinesterase inhibitors and NMDA receptor antagonists to explore novel targets including amyloid-beta aggregation, tau protein phosphorylation, synaptic plasticity, and neuroinflammation. Breakthroughs in genomics and proteomics are helping scientists identify biomarkers and genetic risk factors associated with different types of dementia, enabling more personalized and precise drug development. The introduction of advanced imaging techniques, such as PET scans and MRI-based volumetric analysis, allows for earlier diagnosis and more accurate tracking of disease progression, which is critical for assessing the effectiveness of new therapies. Clinical trial designs are also evolving, with adaptive trial models, real-world data integration, and digital cognitive assessment tools helping researchers gather more meaningful and timely insights. In parallel, pharmaceutical companies are leveraging artificial intelligence and machine learning to accelerate compound discovery, predict therapeutic outcomes, and optimize trial recruitment. Biologics and monoclonal antibodies targeting amyloid and tau proteins are progressing through regulatory pipelines, signaling a shift toward disease-modifying strategies. The accelerated approval of certain amyloid-targeting drugs in some markets, despite controversy, has renewed interest and investment in this area. Additionally, combination therapies that address multiple pathological processes simultaneously are gaining traction as a more comprehensive approach to treating dementia. These scientific and technological innovations are not only expanding the scope of therapeutic possibilities but also redefining the standards for efficacy and safety in the dementia drugs market.

What Trends Are Driving Market Expansion and Investment in Dementia Drug Therapies?

Multiple intersecting trends are fueling the expansion of the global dementia drugs market, reflecting shifts in demographics, healthcare priorities, and investment strategies. One of the most influential trends is the aging population, particularly in regions such as North America, Europe, Japan, and increasingly in parts of Asia and Latin America, where life expectancy is rising. With age being the single greatest risk factor for dementia, these demographic changes are translating into a larger patient base and a sustained market for therapeutic solutions. Simultaneously, public awareness campaigns and education efforts led by organizations such as the Alzheimer’s Association and the World Health Organization are breaking down stigma and encouraging earlier medical consultation, thereby increasing diagnosis rates. Healthcare systems are adapting by integrating cognitive screening into routine check-ups for older adults and expanding insurance coverage for dementia-related treatments. There is also a noticeable shift in investor sentiment, with venture capital firms and large pharmaceutical companies showing renewed interest in neurology and neurodegenerative disease research. Strategic partnerships between biotech startups and established drug manufacturers are becoming common, enabling faster innovation and broader clinical development. Additionally, regulators in several countries are showing greater flexibility in approving dementia treatments, especially those addressing unmet medical needs, which is accelerating market entry for promising candidates. Market diversification is another trend, with drug developers exploring therapies for various types of dementia, including vascular dementia, frontotemporal dementia, and Lewy body dementia, beyond Alzheimer’s disease. This broadening scope is ensuring that the market remains dynamic and responsive to a wider range of clinical presentations and patient needs.

What Are the Primary Drivers Propelling the Growth of the Dementia Drugs Market Worldwide?

The growth in the dementia drugs market is being driven by a convergence of medical, demographic, technological, and economic factors that collectively underscore the urgency and opportunity for therapeutic intervention. A primary driver is the exponential rise in dementia cases globally, spurred by aging populations and increased longevity, particularly in developed economies. This demographic shift is creating a continuously expanding pool of patients in need of long-term medical care, thus elevating the demand for effective pharmacological treatments. Another critical driver is the heightened focus on early diagnosis, which is being facilitated by improvements in diagnostic imaging, biomarker identification, and cognitive assessment tools. Earlier intervention increases the likelihood of therapeutic benefit and opens the door for preventive or disease-modifying strategies. Pharmaceutical and biotech companies are responding to this opportunity with aggressive investment in research and development, often backed by government grants and philanthropic funding. The evolution of regulatory frameworks, which now support fast-track approval pathways for drugs addressing significant unmet needs, is further encouraging innovation. Increasing global health expenditures, particularly in neurology and geriatric care, are enabling broader access to both existing and emerging therapies. Patient advocacy and caregiver support networks are also playing a role by driving demand for better treatment options and influencing public policy. Technological integration in clinical trials and drug delivery mechanisms is making it easier to monitor treatment outcomes and personalize care. These drivers, coupled with a growing recognition of the socioeconomic burden posed by dementia, are ensuring that the market for dementia drugs continues to grow, innovate, and adapt to the complex challenges of neurodegenerative disease management.

SCOPE OF STUDY:

The report analyzes the Dementia Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indications (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, Other Indications); Drug Class (MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class, Cholinesterase Inhibitors Drug Class)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Acadia Pharmaceuticals
  • Amneal Pharmaceuticals
  • Biogen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • GSK plc
  • Grifols, S.A.
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Dementia Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Global Population Throws the Spotlight on Long-Term Demand for Dementia Therapeutics
    • Surge in Early Diagnosis Rates Expands the Addressable Market for Dementia Drugs
    • Breakthroughs in Biomarker Research Strengthen the Business Case for Targeted Therapies
    • Regulatory Fast-Track Approvals Propel Growth of Novel Drug Candidates
    • Growing Caregiver Burden Drives Adoption of Symptom-Management Medications
    • Increased Awareness and Screening Programs Spur Uptake of Preventive Drug Therapies
    • Advances in Disease-Modifying Treatments Reshape the Therapeutic Landscape and Fuel Market Expansion
    • Rising Incidence of Alzheimer's and Related Dementias Creates Structural Growth Opportunities
    • Digital Therapeutics Integration Strengthens Value Proposition of Combined Drug Therapies
    • Evolving Reimbursement Policies Sustain Growth by Improving Drug Accessibility
    • Artificial Intelligence in Drug Discovery Drives Efficiency and Pipeline Innovation
    • Demand for Personalized Medicine Spurs Development of Genetically Tailored Dementia Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dementia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Dementia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lewy Body Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lewy Body Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lewy Body Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parkinson's Disease Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parkinson's Disease Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parkinson's Disease Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Alzheimer's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Alzheimer's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Vascular Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Vascular Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Vascular Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for MAO Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for MAO Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for MAO Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Glutamate Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Glutamate Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Glutamate Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cholinesterase Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Cholinesterase Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • JAPAN
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • CHINA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • EUROPE
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Dementia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • FRANCE
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • GERMANY
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Dementia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • INDIA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Dementia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Dementia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Dementia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030
  • AFRICA
    • Dementia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Dementia Drugs by Indications - Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Dementia Drugs by Indications - Percentage Breakdown of Value Sales for Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Dementia Drugs by Drug Class - MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Dementia Drugs by Drug Class - Percentage Breakdown of Value Sales for MAO Inhibitors Drug Class, Glutamate Inhibitors Drug Class and Cholinesterase Inhibitors Drug Class for the Years 2014, 2025 & 2030

IV. COMPETITION